Caroline Humer

New York

Health Editor at Reuters

health & pharma, for Reuters

Featured in: Favicon

reuters.com

Articles

Weight-loss company Noom pivots to smaller doses of compounded Wegovy

2 weeks ago | today.westlaw.com | Amina Niasse |Bill Berkrot |Caroline Humer

NEW YORK (Reuters) -Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy as the U.S. drugs regulator clamps down on mass production of copies of the in-demand medicine.
Explainer: What Has Trump Said About Cutting Drug Prices?

3 weeks ago | fastbull.com | Maggie Fick |Caroline Humer |Bill Berkrot

May 12 (Reuters) - U.S. President Donald Trump signed a broad executive order on Monday directing drugmakers to lower the prices of their prescription drugs to align with what other countries pay. White House officials said the government will give drugmakers price targets in the next month, and will take further action within six months if the companies do not make "significant progress" toward the goal of lower prices.
Pharma imports to US surged in March as drugmakers look to avoid tariffs

1 month ago | today.westlaw.com | Dan Burns |Bill Berkrot |Michael Erman |Caroline Humer

NEW YORK (Reuters) -Pharmaceutical imports to the U.S. surged in March as drugmakers stocked up ahead of potential U.S. tariffs on their products, which have historically been exempt from such fees.
Exclusive-US cancels FDA bargaining session over layoffs, union says

1 month ago | today.westlaw.com | Bill Berkrot |Patrick Wingrove |Daniel Wiessner |Caroline Humer

(Reuters) -The Trump administration last week canceled the first bargaining session scheduled with the U.S. Food and Drug Administration's largest workers union since its ability to represent government staff was temporarily restored by a federal...
Exclusive-US FDA asks some fired pharma user fee negotiation staff to return

1 month ago | today.westlaw.com | Bill Berkrot |Patrick Wingrove |Caroline Humer

(Reuters) -The U.S. Food and Drug Administration is asking some of its recently fired staff responsible for critically important funding negotiations with drugmakers to return, three sources close to the matter said. The staff being asked back are...
Exclusive-FDA fires most negotiators for pharma user fee talks, sources say

1 month ago | today.westlaw.com | Maggie Fick |Jamie Freed |Marisa Taylor |Caroline Humer

LONDON/WASHINGTON (Reuters) -The U.S. Food and Drug Administration's mass layoffs included senior negotiators in talks with the pharmaceutical industry over renewing the user fee programs that fund the regulator's drug review system, six sources...
US measles battle hindered by confusion over health secretary response

1 month ago | today.westlaw.com | Bill Berkrot |Caroline Humer |Julie Steenhuysen

CHICAGO (Reuters) -U.S. pediatricians and infectious disease experts say the fight against rising measles cases nationwide is being hampered by a lack of forceful advocacy for vaccination from government health officials and statements on unproven...
Exclusive-FDA staff struggle to meet product review deadlines after DOGE layoffs

2 months ago | today.westlaw.com | Bill Berkrot |Michele Gershberg |Patrick Wingrove |Caroline Humer

(Reuters) -Some U.S. health regulators who review medical devices and tobacco products for safety and efficacy are struggling to meet deadlines mandated by Congress due to Trump administration layoffs, three scientists working on the projects told...
Trump healthcare price transparency order may not bring intended relief to patients

2 months ago | today.westlaw.com | Amina Niasse |Bill Berkrot |Caroline Humer

NEW YORK (Reuters) -A Trump administration executive order intended to provide patients with the prices from hospitals and insurers they need to shop around may prove ineffective because of the huge amount of unorganized data it will generate,...
Gene therapy loses luster as investors eye quicker returns from weight-loss drugs

2 months ago | kfgo.com | Deena Beasley |Caroline Humer

By Deena Beasley(Reuters) -Gene therapy, with its offer of a possible cure for rare diseases like sickle cell, is losing early investors to higher-reward sectors like obesity and cancer, as sales for some of the new treatments fall short. In the last year, some drugmakers have pulled back from the sector, including Pfizer, which recently stopped selling its gene therapy for hemophilia priced at $3.5 million per patient.